LBA4000 Background: EGFR overexpression occurs in 27-50% of esophagogastric
adenocarcinomas (OGA), and correlates with poor prognosis. The REAL3 trial evaluated the …

Purpose Epirubicin, oxaliplatin, and capecitabine (EOC) is a standard treatment in advanced
esophagogastric cancer. Panitumumab (P) is a fully human, immunoglobulin G2 monoclonal …

Background EGFR overexpression occurs in 27–55% of oesophagogastric
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …

Background: This randomised phase II study evaluated the efficacy and safety of
panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric …

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …

LBA4017 Background: The aim was to establish the potential use of the third generation
platinum compound, oxaliplatin (O) & the oral fluoropyrimidine capecitabine (X) in untreated …

Background. Esophageal and gastric cancers often present at an advanced stage. Systemic
chemotherapy is the mainstay of treatment, but survival with current regimens remains poor …

The optimal second-and third-line chemotherapy and targeted therapy for patients with
advanced esophagogastric cancer is still a matter of debate. Therefore, a literature search …

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer
(ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor …

4028 Background: ECF (epirubicin, cisplatin and 5FU) is widely used for the treatment of
advanced OG cancer. ECX, where capecitabine is substituted for 5FU has demonstrated …